Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Frontiers in Microbiology|May 23, 2022
Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype MiceFerran Tarrés-Freixas, Benjamin Trinité, Anna Pons-Grífols, et al.
Open Forum Infectious Diseases|August 2, 2021
Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case ReportMarta Massanella, Anabel Martin-Urda, Lourdes Mateu, et al.
Iscience|November 2, 2022
Kinetics of immune responses elicited after three mRNA COVID-19 vaccine doses in predominantly antibody-deficient individualsErola Ainsua-Enrich, Núria Pedreño-Lopez, Carmen Bracke, et al.
Nature Communications|March 22, 2024
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infectionCarlos Ávila-Nieto, Júlia Vergara-Alert, Pep Amengual-Rigo, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 28, 2023
Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2Jordana Muñoz-Basagoiti, Fábio Luís Lima Monteiro, Lauren R H Krumpe, et al.
Frontiers in Immunology|December 21, 2023
Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variantCarlos Ávila-Nieto, Júlia Vergara-Alert, Pep Amengual-Rigo, et al.
Nature Communications|August 7, 2021
Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronavirusesNatalia Ortega, Marta Ribes, Marta Vidal, et al.
Iscience|February 7, 2023
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2Antonio Barreiro, Antoni Prenafeta, Gregori Bech-Sabat, et al.
Vaccine|January 14, 2025
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trialJúlia Corominas, Carme Garriga, Antoni Prenafeta, et al.
The Lancet Regional Health. Europe|May 3, 2023
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trialJúlia Corominas, Carme Garriga, Antoni Prenafeta, et al.
Pageof 6